Christopher K. Murray
CIK 1718648 · CHIEF TECHNICAL OPERATIONS · last filed 2024-03-11
Christopher K. Murray is a CHIEF TECHNICAL OPERATIONS who has filed 23 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing, for BPMC, was dated Jan 23, 2025. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BPMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
38 SIDNEY STREET, SUITE 200
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) Delisted | CHIEF TECHNICAL OPERATIONS | 33,853 | $129.46 | $4.38M | -$1.86M | 17 | 2024-03-11 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-23 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −2,500 | -$277.7K | EDGAR |
| 2025-01-17 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −2,500 | -$259.9K | EDGAR |
| 2024-03-11 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −2,521 | -$228.6K | EDGAR |
| 2024-03-06 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | +11,879 | -$58.2K | EDGAR |
| 2024-03-04 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −621 | -$58.2K | EDGAR |
| 2024-03-01 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$229.3K | EDGAR |
| 2024-02-28 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,000 | -$500.0K | EDGAR |
| 2023-12-11 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$104.3K | EDGAR |
| 2023-12-07 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,000 | -$375.0K | EDGAR |
| 2023-12-06 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −600 | -$42.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.